Minerva Neurosciences (NERV) Competitors

Minerva Neurosciences logo
$2.16 -0.04 (-1.82%)
Closing price 04:00 PM Eastern
Extended Trading
$2.17 +0.01 (+0.42%)
As of 04:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

NERV vs. EOLS, OCS, AQST, ASMB, and RLMD

Should you buy Minerva Neurosciences stock or one of its competitors? Minerva Neurosciences's main competitors and comparable companies include Evolus (EOLS), Oculis (OCS), Aquestive Therapeutics (AQST), Assembly Biosciences (ASMB), and Relmada Therapeutics (RLMD). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Minerva Neurosciences compare to Evolus?

Evolus (NASDAQ:EOLS) and Minerva Neurosciences (NASDAQ:NERV) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, institutional ownership, analyst recommendations, risk, valuation, media sentiment, dividends and profitability.

90.7% of Evolus shares are held by institutional investors. Comparatively, 34.6% of Minerva Neurosciences shares are held by institutional investors. 5.0% of Evolus shares are held by company insiders. Comparatively, 1.7% of Minerva Neurosciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Minerva Neurosciences has a net margin of 0.00% compared to Evolus' net margin of -9.56%.

Company Net Margins Return on Equity Return on Assets
Evolus-9.56% N/A -11.10%
Minerva Neurosciences N/A N/A -28.95%

Evolus has higher revenue and earnings than Minerva Neurosciences. Evolus is trading at a lower price-to-earnings ratio than Minerva Neurosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Evolus$325.47M1.36-$51.64M-$0.47N/A
Minerva NeurosciencesN/AN/A-$293.42M-$28.70N/A

In the previous week, Evolus had 14 more articles in the media than Minerva Neurosciences. MarketBeat recorded 16 mentions for Evolus and 2 mentions for Minerva Neurosciences. Evolus' average media sentiment score of 0.75 beat Minerva Neurosciences' score of 0.16 indicating that Evolus is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Evolus
4 Very Positive mention(s)
1 Positive mention(s)
6 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Minerva Neurosciences
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Neutral

Evolus has a beta of 1.38, suggesting that its stock price is 38% more volatile than the broader market. Comparatively, Minerva Neurosciences has a beta of 0.09, suggesting that its stock price is 91% less volatile than the broader market.

Evolus currently has a consensus target price of $15.00, indicating a potential upside of 124.22%. Minerva Neurosciences has a consensus target price of $10.33, indicating a potential upside of 378.40%. Given Minerva Neurosciences' higher possible upside, analysts plainly believe Minerva Neurosciences is more favorable than Evolus.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Evolus
1 Sell rating(s)
1 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.50
Minerva Neurosciences
1 Sell rating(s)
2 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

Summary

Evolus beats Minerva Neurosciences on 11 of the 14 factors compared between the two stocks.

How does Minerva Neurosciences compare to Oculis?

Minerva Neurosciences (NASDAQ:NERV) and Oculis (NASDAQ:OCS) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, media sentiment, risk, analyst recommendations, dividends, valuation and profitability.

Minerva Neurosciences has a net margin of 0.00% compared to Oculis' net margin of -8,613.92%. Minerva Neurosciences' return on equity of 0.00% beat Oculis' return on equity.

Company Net Margins Return on Equity Return on Assets
Minerva NeurosciencesN/A N/A -28.95%
Oculis -8,613.92%-39.24%-33.45%

Minerva Neurosciences presently has a consensus price target of $10.33, indicating a potential upside of 378.40%. Oculis has a consensus price target of $38.57, indicating a potential upside of 413.60%. Given Oculis' stronger consensus rating and higher probable upside, analysts clearly believe Oculis is more favorable than Minerva Neurosciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Minerva Neurosciences
1 Sell rating(s)
2 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Oculis
1 Sell rating(s)
0 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
2.75

In the previous week, Oculis had 6 more articles in the media than Minerva Neurosciences. MarketBeat recorded 8 mentions for Oculis and 2 mentions for Minerva Neurosciences. Oculis' average media sentiment score of 0.76 beat Minerva Neurosciences' score of 0.16 indicating that Oculis is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Minerva Neurosciences
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Neutral
Oculis
2 Very Positive mention(s)
2 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Oculis has higher revenue and earnings than Minerva Neurosciences. Oculis is trading at a lower price-to-earnings ratio than Minerva Neurosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Minerva NeurosciencesN/AN/A-$293.42M-$28.70N/A
Oculis$1.45M300.30-$119.44M-$1.71N/A

Minerva Neurosciences has a beta of 0.09, suggesting that its share price is 91% less volatile than the broader market. Comparatively, Oculis has a beta of 0.67, suggesting that its share price is 33% less volatile than the broader market.

34.6% of Minerva Neurosciences shares are held by institutional investors. Comparatively, 22.3% of Oculis shares are held by institutional investors. 1.7% of Minerva Neurosciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Oculis beats Minerva Neurosciences on 9 of the 15 factors compared between the two stocks.

How does Minerva Neurosciences compare to Aquestive Therapeutics?

Minerva Neurosciences (NASDAQ:NERV) and Aquestive Therapeutics (NASDAQ:AQST) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, institutional ownership, valuation, risk, analyst recommendations, profitability, dividends and earnings.

Minerva Neurosciences has a net margin of 0.00% compared to Aquestive Therapeutics' net margin of -162.33%.

Company Net Margins Return on Equity Return on Assets
Minerva NeurosciencesN/A N/A -28.95%
Aquestive Therapeutics -162.33%N/A -57.35%

34.6% of Minerva Neurosciences shares are owned by institutional investors. Comparatively, 32.5% of Aquestive Therapeutics shares are owned by institutional investors. 1.7% of Minerva Neurosciences shares are owned by insiders. Comparatively, 6.8% of Aquestive Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, Aquestive Therapeutics had 3 more articles in the media than Minerva Neurosciences. MarketBeat recorded 5 mentions for Aquestive Therapeutics and 2 mentions for Minerva Neurosciences. Aquestive Therapeutics' average media sentiment score of 1.06 beat Minerva Neurosciences' score of 0.16 indicating that Aquestive Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Minerva Neurosciences
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Neutral
Aquestive Therapeutics
2 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Positive

Minerva Neurosciences presently has a consensus target price of $10.33, indicating a potential upside of 378.40%. Aquestive Therapeutics has a consensus target price of $8.75, indicating a potential upside of 136.49%. Given Minerva Neurosciences' higher probable upside, equities analysts clearly believe Minerva Neurosciences is more favorable than Aquestive Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Minerva Neurosciences
1 Sell rating(s)
2 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Aquestive Therapeutics
1 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.50

Aquestive Therapeutics has higher revenue and earnings than Minerva Neurosciences. Aquestive Therapeutics is trading at a lower price-to-earnings ratio than Minerva Neurosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Minerva NeurosciencesN/AN/A-$293.42M-$28.70N/A
Aquestive Therapeutics$44.54M10.44-$83.78M-$0.64N/A

Minerva Neurosciences has a beta of 0.09, indicating that its share price is 91% less volatile than the broader market. Comparatively, Aquestive Therapeutics has a beta of 1.49, indicating that its share price is 49% more volatile than the broader market.

Summary

Aquestive Therapeutics beats Minerva Neurosciences on 9 of the 14 factors compared between the two stocks.

How does Minerva Neurosciences compare to Assembly Biosciences?

Minerva Neurosciences (NASDAQ:NERV) and Assembly Biosciences (NASDAQ:ASMB) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, risk, earnings, profitability, media sentiment, institutional ownership, dividends and analyst recommendations.

Minerva Neurosciences currently has a consensus price target of $10.33, suggesting a potential upside of 378.40%. Assembly Biosciences has a consensus price target of $46.50, suggesting a potential upside of 106.67%. Given Minerva Neurosciences' higher probable upside, equities analysts clearly believe Minerva Neurosciences is more favorable than Assembly Biosciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Minerva Neurosciences
1 Sell rating(s)
2 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Assembly Biosciences
1 Sell rating(s)
1 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.50

34.6% of Minerva Neurosciences shares are owned by institutional investors. Comparatively, 19.9% of Assembly Biosciences shares are owned by institutional investors. 1.7% of Minerva Neurosciences shares are owned by insiders. Comparatively, 3.5% of Assembly Biosciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Assembly Biosciences has higher revenue and earnings than Minerva Neurosciences. Minerva Neurosciences is trading at a lower price-to-earnings ratio than Assembly Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Minerva NeurosciencesN/AN/A-$293.42M-$28.70N/A
Assembly Biosciences$72.30M6.34-$6.12M$0.8127.78

Minerva Neurosciences has a net margin of 0.00% compared to Assembly Biosciences' net margin of -16.57%. Minerva Neurosciences' return on equity of 0.00% beat Assembly Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Minerva NeurosciencesN/A N/A -28.95%
Assembly Biosciences -16.57%-4.68%-4.04%

In the previous week, Assembly Biosciences had 5 more articles in the media than Minerva Neurosciences. MarketBeat recorded 7 mentions for Assembly Biosciences and 2 mentions for Minerva Neurosciences. Minerva Neurosciences' average media sentiment score of 0.16 beat Assembly Biosciences' score of -0.77 indicating that Minerva Neurosciences is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Minerva Neurosciences
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Neutral
Assembly Biosciences
0 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
1 Negative mention(s)
1 Very Negative mention(s)
Negative

Minerva Neurosciences has a beta of 0.09, suggesting that its share price is 91% less volatile than the broader market. Comparatively, Assembly Biosciences has a beta of 1.26, suggesting that its share price is 26% more volatile than the broader market.

Summary

Assembly Biosciences beats Minerva Neurosciences on 10 of the 15 factors compared between the two stocks.

How does Minerva Neurosciences compare to Relmada Therapeutics?

Relmada Therapeutics (NASDAQ:RLMD) and Minerva Neurosciences (NASDAQ:NERV) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, dividends, media sentiment, risk, analyst recommendations, valuation and institutional ownership.

In the previous week, Relmada Therapeutics had 19 more articles in the media than Minerva Neurosciences. MarketBeat recorded 21 mentions for Relmada Therapeutics and 2 mentions for Minerva Neurosciences. Relmada Therapeutics' average media sentiment score of 0.78 beat Minerva Neurosciences' score of 0.16 indicating that Relmada Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Relmada Therapeutics
3 Very Positive mention(s)
1 Positive mention(s)
5 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Positive
Minerva Neurosciences
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Neutral

Relmada Therapeutics has a beta of 0.62, indicating that its share price is 38% less volatile than the broader market. Comparatively, Minerva Neurosciences has a beta of 0.09, indicating that its share price is 91% less volatile than the broader market.

Relmada Therapeutics is trading at a lower price-to-earnings ratio than Minerva Neurosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Relmada TherapeuticsN/AN/A-$57.38M-$0.72N/A
Minerva NeurosciencesN/AN/A-$293.42M-$28.70N/A

45.2% of Relmada Therapeutics shares are held by institutional investors. Comparatively, 34.6% of Minerva Neurosciences shares are held by institutional investors. 14.5% of Relmada Therapeutics shares are held by company insiders. Comparatively, 1.7% of Minerva Neurosciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Relmada Therapeutics currently has a consensus target price of $12.00, suggesting a potential upside of 298.67%. Minerva Neurosciences has a consensus target price of $10.33, suggesting a potential upside of 378.40%. Given Minerva Neurosciences' higher probable upside, analysts clearly believe Minerva Neurosciences is more favorable than Relmada Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Relmada Therapeutics
1 Sell rating(s)
1 Hold rating(s)
5 Buy rating(s)
1 Strong Buy rating(s)
2.75
Minerva Neurosciences
1 Sell rating(s)
2 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

Minerva Neurosciences' return on equity of 0.00% beat Relmada Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Relmada TherapeuticsN/A -38.51% -35.94%
Minerva Neurosciences N/A N/A -28.95%

Summary

Relmada Therapeutics beats Minerva Neurosciences on 10 of the 14 factors compared between the two stocks.

Get Minerva Neurosciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for NERV and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NERV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

NERV vs. The Competition

MetricMinerva NeurosciencesPharmaceuticals IndustryHealthcare SectorNASDAQ Exchange
Market Cap$107.63M$13.61B$7.74B$11.66B
Dividend YieldN/A2.58%2.46%4.42%
P/E Ratio-0.0829.4134.1729.85
Price / SalesN/A7.028.485.62
Price / CashN/A15.7421.9322.50
Price / Book-1.105.114.373.66
Net Income-$293.42M$2.88B$3.52B$392.27M
7 Day Performance-13.25%-4.11%-5.47%-4.72%
1 Month Performance-8.09%-5.09%-4.58%-7.14%
1 Year Performance-50.46%-7.45%-1.79%-7.51%

Minerva Neurosciences Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
NERV
Minerva Neurosciences
2.1875 of 5 stars
$2.16
-1.8%
$10.33
+378.4%
-46.5%$107.63MN/AN/A7
EOLS
Evolus
3.2257 of 5 stars
$6.81
-2.4%
$15.00
+120.3%
-8.2%$461.99M$297.18MN/A353
OCS
Oculis
2.8558 of 5 stars
$7.59
-2.2%
$38.89
+412.4%
-61.1%$449.96M$1.45MN/A60
AQST
Aquestive Therapeutics
2.3303 of 5 stars
$3.52
-0.6%
$8.75
+148.6%
-30.2%$444.93M$44.54MN/A147
ASMB
Assembly Biosciences
1.9238 of 5 stars
$21.35
-2.0%
$46.50
+117.8%
-42.0%$443.66M$72.30M21.3673

Related Companies and Tools


This page (NASDAQ:NERV) was last updated on 11/17/2026 by MarketBeat.com Staff.
From Our Partners